Drugs / Vonoprazan
Vonoprazan
also known as
TAK-438 · vonoprazan Fumarate · vocinti · VPZ · TAK-438 monofumarate · Takecab · Vonaspire · Vonoprazan monofumarate · +2 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VOQUEZNA TRIPLE PAK | — | 2022-05-03 | fda.gov ↗ |
Trials 102 · started per year
today
US approved 2022
2
2
1
8
6
1
2
5
4
4
4
15
12
8
10
13
5
20082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05005910 | Sep 2021 → Dec 2022 | peptic ulcer disease | Uayporn Kaosombatwattana | Completed | No outcome recorded |
| Phase 117 trials | ||||||
| Phase 1 | NCT06831344 | Feb → Apr 2025 | — | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06391177 | May → Sep 2024 | Helicobacter pylori infectious disease, dyspepsia, esophagitis, gastroesophageal reflux disease | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06106022 | Nov 2023 → Apr 2024 | gastroesophageal reflux disease | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05366738 | May → Jul 2022 | — | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05343364 | May 2022 → May 2023 | gastroesophageal reflux disease | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04753437 | Apr → Sep 2021 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT04729101 | Jan → Jun 2021 | — | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04568772 | Nov 2020 → Jul 2021 | gastroesophageal reflux disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04558216 | Sep 2020 → Feb 2021 | — | Phathom Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04545944 | Sep → Nov 2020 | — | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03085836 | Apr → Aug 2017 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02892409 | Sep 2016 → Apr 2017 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02774902 | Aug → Sep 2010 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02123953 | Oct 2008 → Mar 2009 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02141711 | Oct 2008 → Feb 2009 | esophagitis, gastroesophageal reflux disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02141698 | Oct 2007 → Feb 2008 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02123927 | Sep → Dec 2007 | — | Takeda | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07275632 | Dec 2025 → Oct 2026 expected | — | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07267260 | Dec 2025 → Jan 2026 overdue | cirrhosis of liver | King Edward Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06851559 | Oct 2025 → Oct 2026 expected | eosinophilic esophagitis | Phathom Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04799158 | Mar → Dec 2021 | dyspepsia, gastroesophageal reflux disease | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02743949 | Jul 2016 → Oct 2018 | gastroesophageal reflux disease | Takeda | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07242456 | Feb → Nov 2025 overdue | Helicobacter pylori infectious disease | First People's Hospital of Hangzhou | Recruiting | No outcome recorded |
| Phase 331 trials | ||||||
| Phase 3 | NCT07608536 | May → Jul 2026 overdue | esophageal varices | King George's Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06576882 | Jun → Nov 2024 | Helicobacter pylori infectious disease, gastritis | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT06162949 | Jan → Aug 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT05719831 | Feb → Sep 2023 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT05227833 | Feb → Nov 2022 | esophageal varices with bleeding, portal hypertension, ulcer disease | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT05195528 | Jan → Nov 2022 | dyspepsia, gastroesophageal reflux disease | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06101420 | Jan 2022 → Jun 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04198363 | Apr 2020 → Nov 2021 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT04167670 | Dec 2019 → Mar 2021 | Helicobacter pylori infectious disease | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04124926 | Oct 2019 → Jul 2021 | esophagitis | Phathom Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03050307 | Apr 2017 → Feb 2020 | gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03050359 | Apr 2017 → Mar 2019 | duodenal ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02954848 | Nov 2016 → Feb 2018 | gastroesophageal reflux disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02827942 | Jul 2016 → Dec 2018 | bacterial gastritis | Hamamatsu University | Completed | No outcome recorded |
| Phase 3 | NCT02388737 | Apr 2015 → Dec 2018 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02388724 | Mar 2015 → Jul 2017 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02037477 | Jan → Mar 2014 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01630746 | Jul 2012 → Sep 2013 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01568398 | May 2012 → Aug 2013 | duodenal ulcer, gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01568385 | Apr 2012 → Sep 2013 | duodenal ulcer, gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01456247 | Mar 2012 → Oct 2013 | duodenal ulcer, gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01505127 | Jan 2012 → Jun 2013 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01474369 | Dec 2011 → Feb 2013 | gastroesophageal reflux disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01452711 | Nov 2011 → Dec 2012 | gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01452724 | Oct 2011 → Feb 2013 | duodenal ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01452763 | Oct 2011 → Apr 2013 | duodenal ulcer, gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01452750 | Oct 2011 → Jun 2013 | duodenal ulcer, gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01459367 | Oct 2011 → Mar 2013 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01456260 | Sep 2011 → Dec 2013 | duodenal ulcer, gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01452776 | Sep 2011 → Jul 2013 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01452698 | ? → Aug 2012 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase 433 trials | ||||||
| Phase 4 | NCT07537634 | Apr → Aug 2026 overdue | Helicobacter pylori infectious disease, dyspepsia, peptic ulcer disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Phase 4 | NCT07232095 | Jan 2026 → Jun 2027 expected | Helicobacter pylori infectious disease | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT07040839 | Jul 2025 → Feb 2026 overdue | Helicobacter pylori infectious disease | Rehman Medical Institute - RMI | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07344506 | May 2025 → May 2026 overdue | Helicobacter pylori infectious disease | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06929962 | Apr 2025 → Dec 2026 expected | Helicobacter pylori infectious disease | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT07068607 | Apr → Oct 2025 overdue | Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 | Yongquan Shi | Recruiting | No outcome recorded |
| Phase 4 | NCT06723197 | Dec 2024 → Oct 2025 overdue | Helicobacter pylori infectious disease | Shandong University | Recruiting | No outcome recorded |
| Phase 4 | NCT06720610 | Dec 2024 → Apr 2025 overdue | esophagitis | Indonesia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06514274 | Sep 2024 → Apr 2025 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT06561698 | Aug 2024 → Aug 2026 overdue | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06526455 | Aug 2024 → Jun 2029 expected | gastric ulcer | Shicai Ye | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06156085 | Nov 2023 → Nov 2024 | Helicobacter pylori infectious disease | Fu Jen Catholic University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06168214 | Sep 2023 → Nov 2024 overdue | — | Xijing Hospital of Digestive Diseases | Recruiting | No outcome recorded |
| Phase 4 | NCT06168084 | Jun 2023 → May 2024 | stomach disorder | Yongquan Shi | Completed | No outcome recorded |
| Phase 4 | NCT05582174 | May 2023 → Jan 2028 expected | active peptic ulcer disease | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT04728516 | Apr 2023 → Jun 2026 overdue | Helicobacter pylori infectious disease, acute coronary syndrome | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 4 | NCT07224035 | Oct 2022 → Nov 2027 expected | Helicobacter pylori infectious disease, gastric cancer, gastritis | University of Miami | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05419674 | Aug 2022 → Aug 2023 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05469685 | Aug 2022 → Aug 2023 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05614934 | Jun 2022 → May 2023 | Helicobacter pylori infectious disease | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT05590286 | Jun 2022 → Dec 2024 | Helicobacter pylori infectious disease, proton-pump inhibitor-responsive esophageal eosinophilia | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 4 | NCT05196945 | Mar → Dec 2022 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT05371249 | Dec 2021 → Dec 2023 | Helicobacter pylori infectious disease | Fu Jen Catholic University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05014334 | Dec 2021 → Mar 2022 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT05049902 | Sep 2021 → May 2023 | Helicobacter pylori infectious disease | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT04901663 | Jun → Aug 2021 | Helicobacter pylori infectious disease | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT04901117 | Jun 2021 → Jun 2023 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT04907747 | May 2021 → Apr 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04713670 | Mar 2021 → Dec 2025 overdue | Helicobacter pylori infectious disease | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04028466 | May 2019 → Mar 2020 | gastroesophageal reflux disease | St. Luke's Medical Center, Philippines | Terminated | No outcome recorded |
| Phase 4 | NCT03908619 | Apr 2019 → Mar 2021 | Helicobacter pylori infectious disease | Changi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03116841 | Aug → Dec 2017 | peptic esophagitis | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02679508 | Mar 2016 → Mar 2022 | esophagitis | Takeda | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT07439445 | Apr 2026 → Feb 2027 expected | Helicobacter pylori infectious disease | Peking University First Hospital | Recruiting | No outcome recorded |
| — | NCT07352098 | Feb 2026 → Feb 2028 expected | Helicobacter pylori infectious disease | Yueyue Li | Not yet recruiting | No outcome recorded |
| — | NCT07437768 | Dec 2025 → Feb 2026 overdue | gastroesophageal reflux disease | Fu Jen Catholic University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06953986 | Dec 2025 → Nov 2026 expected | gastroesophageal reflux disease | Asian Institute of Gastroenterology, India | Recruiting | No outcome recorded |
| — | NCT07165444 | Sep 2025 → Feb 2026 overdue | Helicobacter pylori infectious disease, proton-pump inhibitor-responsive esophageal eosinophilia | Tanta University | Recruiting | No outcome recorded |
| — | NCT07563491 | Jan → Sep 2025 | gastroesophageal reflux disease | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT07142798 | Sep 2024 → Dec 2025 overdue | Helicobacter pylori infectious disease | Kaohsiung Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT06250634 | Feb → May 2024 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| — | NCT06004401 | Aug 2023 → Aug 2025 | — | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT05189444 | Mar → Dec 2022 | Helicobacter pylori infectious disease | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT05133193 | Nov 2021 → Jun 2022 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| — | NCT05126121 | Nov 2021 → Jun 2022 | Helicobacter pylori infectious disease | Xiuli Zuo | Unknown | No outcome recorded |
| — | NCT04991584 | Aug 2021 → Jun 2022 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| — | NCT05097846 | Jun 2021 → Jun 2022 | Helicobacter pylori infectious disease | wang xiaoyan | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 39 trials
Press releases naming this drug 14 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-06-07 | Takeda | VONOSAP ® pack 400, VONOSAP ® pack 800 and VONOPION ® pack (triple-drug blister packs containing TAKECAB ® tablet) Now Available for Helicobacter pylori [*] Eradication in Japan takeda.com ↗ |
| 2016-06-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VONOSAP pack 400, VONOSAP pack 800 and VONOPIONpack (triple-drug blister packs containing TAKECAB® tablet) Now Available for Eradication in Japan®®®Helicobacter pylori* otsuka.co.jp ↗ |
| 2016-02-26 | Takeda | Takeda Obtains New Drug Application Approval for Helicobacter pylori [※] Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP ® pack 400", "VONOSAP ® pack 800" and "VONOPION ® pack" in Japan takeda.com ↗ |
| 2016-02-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Takeda Obtains NDA Approval for Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP pack 400", "VONOSAP pack 800" and "VONOPION pack" in JapanHelicobacter pylori*®®® otsuka.co.jp ↗ |
| 2015-03-26 | Takeda | New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan takeda.com ↗ |
| 2015-03-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan otsuka.co.jp ↗ |
| 2015-02-26 | Takeda | TAKECAB ® Now Available for the Treatment of Acid-related Diseases in Japan takeda.com ↗ |
| 2015-02-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan otsuka.co.jp ↗ |
| 2014-12-26 | Takeda | New Drug Application Approval of TAKECAB ® for the treatment of Acid-related Diseases in Japan takeda.com ↗ |
| 2014-12-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New Drug Application Approval of TAKECAB for the Treatment of Acid-related Diseases in Japan® otsuka.co.jp ↗ |
| 2014-05-07 | Takeda | Presentation of Highlight Results from recent Phase 3 Trials of Vonoprazan Fumarate for the Treatment of Acid-related Diseases at the DDW 2014 Meeting takeda.com ↗ |
| 2014-03-27 | Takeda | Otsuka and Takeda Announce a Co-promotion Agreement in Japan of TAK-438 For the Treatment of Acid-related Diseases in the Gastrointestinal Therapeutic Area takeda.com ↗ |
| 2014-03-27 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Takeda Announce a Co-promotion Agreement in Japan of TAK-438 For the Treatment of Acid-related Diseases in the Gastrointestinal Therapeutic Area otsuka.co.jp ↗ |
| 2014-02-28 | Takeda | Takeda Submits a New Drug Application for TAK-438 in Japan for the Treatment of Acid-related Diseases takeda.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 147 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vonoprazan | “Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in...” PMID 25707624 ↗ Feb 2015116“The eligible patients received 14-day concomitant therapy, including vonoprazan and three kinds of antibiotics according to the previous eradication regimens and antibiotic use.” NCT05133193 ↗ “Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), has a stronger and more sustained inhibitory effect on gastric acid secretion compared to traditional PPIs.” NCT06881524 ↗ “Potassium-competitive acid blockers (P-CABs), such as vonoprazan, provide rapid, consistent, and strong acid suppression regardless of the CYP2C19 genotype.” NCT07165444 ↗ “In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.” NCT02761005 ↗ “2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days” NCT05749081 ↗ “Patients sensitive to clarithromycin are assigned to the Clarithromycin Group (receiving a regimen of vonoprazan, amoxicillin, and clarithromycin)” NCT07533422 ↗ “FDA-approved combination therapy for H. pylori infection, consisting of: Vonoprazan tablets 20 mg (1 tablet twice daily for 14 days)” NCT07224035 ↗ “vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days” NCT07142798 ↗ “1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days” NCT05649709 ↗ “Vonoprazan 20mg twice daily+Amoxicillin 1g three times daily+Bismuth 220mg twice daily for 7 days” NCT07232095 ↗ “Vonoprazan has been widely used in the eradication treatment of Hp .” NCT06004401 ↗ “vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)” NCT04713670 ↗ “Vonoprazan [20 mg, bid] plus amoxicillin [1000 mg, tid]” PMID 42141850 ↗ May 2026 “Vonoprazan: Potassium competitive acid blocker” NCT07293910 ↗ |
| Known as | TAK-438 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02123953 ↗23 |
| Known as | TAK-438 monofumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2079130 ↗ |
| Known as | Takecab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2079130 ↗ |
| Known as | vocinti | “Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid” NCT04901117 ↗3“Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid” NCT05049902 ↗ “Patients then received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®).” NCT07437768 ↗ “vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)” NCT04713670 ↗ |
| Known as | Vonaspire | “Vonoprazan fumarate (Vonaspire)” NCT05227833 ↗ |
| Known as | vonoprazan Fumarate | “BACKGROUND: Vonoprazan fumarate is a novel potassium-competitive acid blocker more effective in suppressing acid production than proton pump inhibitors (PPIs) and when combined...” PMID 34247436 ↗ Jul 20217“1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days” NCT05649709 ↗ “vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral” NCT05196945 ↗ “Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid” NCT04901117 ↗ “Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid” NCT05049902 ↗ “received vonoprazan fumarate tablets 20 mg three times daily” NCT07352098 ↗ “Vonoprazan fumarate (Vonaspire)” NCT05227833 ↗ |
| Known as | Vonoprazan monofumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2079130 ↗ |
| Known as | Vonseca | “Vonoprazan 20mg (Vonseca) and placebo of pantoprazole (pantoloc) daily for 8 weeks” NCT06564246 ↗ |
| Known as | Voquezna | ChEMBL registry synonym — accepted as the source's own label CHEMBL2079130 ↗ |
| Known as | VPZ | “The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for Helicobacter pylori (H. pylori).” PMID 35719338 ↗ Jun 20221“Vonoprazan (VPZ) produces a strong acid-inhibitory effect” PMID 37214450 ↗ May 2023 |
| Action | Inhibit | “potassium-competitive acid blocker” PMID 27891632 ↗ Nov 2016 |
| Modality | Other / unclassified | “a potassium-competitive acid blocker” PMID 25707624 ↗ Feb 2015 |
| Route | Oral | “TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.” NCT01452698 ↗ |